Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-pvvr and Abatacept in New Onset Type 1 Diabetes
NCT03929601Phase 2Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2023
- Primary completion
- Mar 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Rituximab-pvvr followed by Abatacept with Rituximab-pvvr followed by Placebo (2 arms). Primary endpoint: C-Peptide Response to 2-hr Mixed Meal Tolerance Test (MMTT). Started Oct 2023; status: active, not recruiting.
02
Drugs
abatacept
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03929601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929601.